Use of patient preferences in HTA processes

Learn which role patient preference data can play in HTA processes

Register Get course info

26 Oct 2023

On location

Danish

3,150 DKK ex VAT

(app. 424 EUR ex VAT)

50% DISCOUNT FOR PUBLIC INSTITUTIONS
Home > Courses > Use of patient preferences in HTA processes

Summary

Patient preferences when using medicine is already part of the approval process for new medicines in FDA and EMA and similar procedures are pending within NICE (UK).

At this hot topic seminar, you gain an understanding of how patient perspectives and patient preferences can be used to demonstrate the value of pharmaceutical products. Specifically, you will hear representatives from NICE and the Danish Medicines Council discuss how NICE and The Danish Medicines Council respectively regard such data. 


You will learn from real-life case examples from:

  • Centre for joint decision-making, Lillebælt Hospital
  • Lundbeck
  • NICE

Please note: two lectures are conducted in English, and three lectures will be presented via video link.


Keywords

  • Patient preferences
  • Patient Advocacy
  • Medical Affairs
  • HTA processes
  • NICE

Save information for later
Read more

Course leader & lecturers

  • Elisabeth Gammelgaard Ludvig
    Course leader
    Owner
    Sundhedsagenda
  • Jørgen Schøler Kristensen
    Lecturer
    Kst Koncerndirektør
    Medicinrådet
  • Karina Dahl Steffensen
    Lecturer
    Professor, Cheflæge, Center for Fælles Beslutningstagning
    Sygehus Lillebælt
  • Agathe Le Lay
    Lecturer
    Senior Director and Global Head of Value Evidence
    Lundbeck A/S
See all

Is this course for you?

Join this course if you work in a consultant or pharmaceutical company with medical affairs, market access, public affairs, sales & marketing, and patient advocacy.

What you will learn


  1. Understand what patient preferences are, and how they can be generated qualitatively and quantitatively.
  2. Learn how NICE views patient preference data, and how (& if?) The Danish Medicines Council (Medicinrådet) expects to include patient preferences in its future considerations.
  3. Learn how a pharma HQ works with patient preference data in HTA processes.
  4. Understand how Danish HCPs work with patient involvement and patient preferences in joint decision making when choosing treatment type, and how pharma companies can support this work.

What your company will get


  1. An employee who understands patient preferences and how these can be developed.
  2. An employee who understands how patient preferences can be utilised in cross-functional work within a pharma company in drug development, during market access and during launch.

Course calendar

26 Oct 2023 9:00-12:30

Day 1

  • How do physicians work with patient preferences and joint decision making in the daily clinic?
  • How to use patients’ perspectives and preferences to demonstrate the value of therapeutic interventions
  • Use of patient preference studies in HTA decision making: a perspective from NICE
  • The Danish Medicines Council’s (Medicinrådets) view on patient preference data and their role in the future work of the council
  • Lunch and networking
Practical information

Registration

Registration deadline
26 Oct 2023
Atrium
Lersø Parkallé 101
2100 København Ø
Register
26 Oct
Sometimes things change. This is the expected programme.

Course information

Literature

Prerequisites

Industry knowledge is an advantage.

Examination

There is no examination for this course.

Course leader

Elisabeth Gammelgaard Ludvig
Owner
Sundhedsagenda

Lecturers

Jørgen Schøler Kristensen
Kst Koncerndirektør
Medicinrådet
Karina Dahl Steffensen
Professor, Cheflæge, Center for Fælles Beslutningstagning
Sygehus Lillebælt
Agathe Le Lay
Senior Director and Global Head of Value Evidence
Lundbeck A/S

You may also be interested in these courses

Want to know more or need help?

Contact Client Manager Christina Spangsberg at +45 39 15 09 22